KR102247795B9 - 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물 - Google Patents

급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물

Info

Publication number
KR102247795B9
KR102247795B9 KR1020180131294A KR20180131294A KR102247795B9 KR 102247795 B9 KR102247795 B9 KR 102247795B9 KR 1020180131294 A KR1020180131294 A KR 1020180131294A KR 20180131294 A KR20180131294 A KR 20180131294A KR 102247795 B9 KR102247795 B9 KR 102247795B9
Authority
KR
South Korea
Prior art keywords
inhibiting
treating
composition
breast cancer
myeloid leukemia
Prior art date
Application number
KR1020180131294A
Other languages
English (en)
Other versions
KR20190049584A (ko
KR102247795B1 (ko
Inventor
김용철
유현
정평화
Original Assignee
주식회사 펠레메드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 펠레메드 filed Critical 주식회사 펠레메드
Publication of KR20190049584A publication Critical patent/KR20190049584A/ko
Application granted granted Critical
Publication of KR102247795B1 publication Critical patent/KR102247795B1/ko
Publication of KR102247795B9 publication Critical patent/KR102247795B9/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020180131294A 2017-10-31 2018-10-30 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물 KR102247795B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170144142 2017-10-31
KR20170144142 2017-10-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020210052728A Division KR20210047850A (ko) 2021-04-23 2021-04-23 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물

Publications (3)

Publication Number Publication Date
KR20190049584A KR20190049584A (ko) 2019-05-09
KR102247795B1 KR102247795B1 (ko) 2021-05-04
KR102247795B9 true KR102247795B9 (ko) 2023-04-12

Family

ID=66333236

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020180131294A KR102247795B1 (ko) 2017-10-31 2018-10-30 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물

Country Status (12)

Country Link
US (1) US11370779B2 (ko)
EP (1) EP3705474A4 (ko)
JP (1) JP7005779B2 (ko)
KR (1) KR102247795B1 (ko)
CN (1) CN111542513A (ko)
AU (1) AU2018358582B2 (ko)
BR (1) BR112020008499A2 (ko)
CA (1) CA3080900C (ko)
MX (1) MX2020004374A (ko)
PH (1) PH12020550491A1 (ko)
RU (1) RU2763346C2 (ko)
WO (1) WO2019088677A1 (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110305056A (zh) * 2019-05-22 2019-10-08 西北大学 靛玉红新衍生物及其药用用途
WO2021090172A1 (en) * 2019-11-04 2021-05-14 Ck Biotechnology Co. Compositions and methods for suppressing and/or treating neurodegenerative diseases and/or a clinical condition thereof
KR102443617B1 (ko) * 2019-12-06 2022-09-16 광주과학기술원 근감소증 또는 근위축증의 예방 또는 치료용 약제학적 조성물
WO2021112626A1 (ko) * 2019-12-06 2021-06-10 주식회사 펠레메드 신규한 인디루빈 유도체 및 이의 용도
KR102325607B1 (ko) 2020-02-20 2021-11-12 한국과학기술원 Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조퓨란-피라졸 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물
KR20210106155A (ko) 2020-02-20 2021-08-30 한국과학기술원 Ash1l 히스톤 메틸화 효소 활성을 억제하는 페닐카르보노히드라조노일 디시아나이드 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물
KR102278176B1 (ko) 2020-02-20 2021-07-16 한국과학기술원 Ash1l 히스톤 메틸화 효소 활성을 억제하는 벤조디옥솔 유도체 화합물을 포함하는 백혈병의 예방 또는 치료용 조성물
US20220079934A1 (en) * 2020-09-17 2022-03-17 Arog Pharmaceuticals, Inc. Crenolanib for treating pain

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK14272001A3 (sk) * 1999-04-12 2002-05-09 Gerhard Eisenbrand Indigoidné bisindolové deriváty
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
KR100588803B1 (ko) * 2004-01-27 2006-06-12 학교법인조선대학교 암세포주에 항암활성을 지닌 인디루빈 유도체
WO2007099402A2 (en) 2005-12-23 2007-09-07 Centre National De La Recherche Scientifique (Cnrs) New 3’-, 7-substituted indirubins and their applications
ATE529402T1 (de) 2008-08-01 2011-11-15 Centre Nat Rech Scient 3',6-substituierte indirubine und ihre biologischen anwendungen
KR101180030B1 (ko) * 2010-02-05 2012-09-05 광주과학기술원 사이클린-의존적 키나제 저해제로서 항암 활성을 지닌 인디루빈-3'-옥심 유도체
EP2518139A1 (en) * 2011-04-27 2012-10-31 Universitätsklinikum Jena Use of indirubin derivatives for producing pluripotent stem cells
US10435367B2 (en) * 2013-03-14 2019-10-08 City Of Hope Indirubin derivatives, and uses thereof
EP2827869A4 (en) * 2012-03-23 2015-09-23 Dennis Brown COMPOSITIONS AND METHODS FOR IMPROVING THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ITS ANALOGUES INCLUDING MESOINDIGO
BR112015023383A2 (pt) * 2013-03-14 2017-07-18 Hope City compostocomposição farmacêutica; e método de modulação
US20150259288A1 (en) * 2014-03-14 2015-09-17 City Of Hope 5-bromo-indirubins

Also Published As

Publication number Publication date
PH12020550491A1 (en) 2021-01-11
JP7005779B2 (ja) 2022-02-10
KR20190049584A (ko) 2019-05-09
EP3705474A1 (en) 2020-09-09
EP3705474A4 (en) 2021-06-09
MX2020004374A (es) 2020-11-11
BR112020008499A2 (pt) 2020-10-20
RU2763346C2 (ru) 2021-12-28
WO2019088677A1 (ko) 2019-05-09
CA3080900C (en) 2022-10-25
JP2021501208A (ja) 2021-01-14
US20200270229A1 (en) 2020-08-27
AU2018358582A1 (en) 2020-05-07
RU2020115581A3 (ko) 2021-12-02
RU2020115581A (ru) 2021-12-02
CA3080900A1 (en) 2019-05-09
CN111542513A (zh) 2020-08-14
KR102247795B1 (ko) 2021-05-04
US11370779B2 (en) 2022-06-28
AU2018358582B2 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
KR102247795B9 (ko) 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물
PL3431105T3 (pl) Kompozycja lecznicza do leczenia raka
IL260444B (en) Anti-her2 combinations for cancer treatment
RS63561B1 (sr) Kompozicija za lečenje raka
EP3134115A4 (en) Methods and compositions for treating metastatic breast cancer and other cancers in the brain
RS63311B1 (sr) Ar+ metode lečenja raka dojke
GB201709677D0 (en) Treatment for acute myeloid leukaemia
GB201709405D0 (en) Compounds for treating ovarian cancer
KR102269666B9 (ko) 전이성 난소암, 자궁내막암 또는 유방암의 예방 또는 치료용 조성물
IL265938B (en) Zofoxifene treatment for +er breast cancer
SG11202010528XA (en) Combinations for treating cancer
IL283337A (en) Methods for treating whsc1-overexpressing cancers by inhibiting setd2
ZA201900939B (en) Combination treatment for hematological cancers
PL3296294T3 (pl) Związek do leczenia lub zapobiegania nowotworowi piersi
IL288135A (en) Compounds containing bisfluoroalkyl-1,4-benzodiazepines for the treatment of breast cancer characterized by Notch activation
IL269769B (en) Mixtures, composition and their use for cancer treatment
GB201909468D0 (en) Compounds for treating cancer
IL261160B (en) Methods of treating acute myeloid leukemia
SG11202003967PA (en) Compositions comprising alpha-polyglutamic acid-zinc for treating cancer
IL282692A (en) Compounds derived from madrasin, a preparation and their uses for the treatment of cancer
IL272379A (en) Methods for treating cancer using SETDS inhibition
PL3630754T3 (pl) Związki izoindolinoacetylenowe do leczenia nowotworu
PL3319638T3 (pl) Kompozycja zawierająca cyneol do leczenia chorób nowotworowych i/lub raków
IL282228A (en) A combination solution for the treatment of chemotherapy-resistant cancer
PT3813832T (pt) Compostos para utilização na prevenção ou tratamento de cancro

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
X091 Application refused [patent]
AMND Amendment
X701 Decision to grant (after re-examination)
GRNT Written decision to grant
G170 Re-publication after modification of scope of protection [patent]